Key points are not available for this paper at this time.
Information on bladder cancer (BC) according to the risk scoring for recurrence or progression in a general population is scarce despite its clinical relevance. The objective was to describe the characteristics of incident BC in a general population, with a focus on the initial management of high-risk non-muscle invasive BC (HR-NMIBC). BC incident in 2011–2012 recorded in a population-based cancer registry were studied. Data was extracted from medical files. NMIBC were classified according to potential risk for recurrence/progression. Individual and tumor characteristics of incident BC were described. Incidence, initial management and survival (12/31/2021) of HR-NMIBC were assessed. Among 538 BC cases, 380 were NMIBC 119 low (22.1%), 163 intermediate (30.3%), 98 high (18.2%) risk and 147 (27.3%) were MIBC. HR-NMIBC diagnostic and therapeutic management imaging, re-TUR, multidisciplinary team meetings (MDT) assessment, specific treatment revealed discrepancies with guidelines recommendations. Seventy-two out of 98 cases were assessed in an MDT with a median time from diagnosis of 18 days first quartile: 12-third quartile: 32. Globally, treatment agreed with MDT decisions. Intravesical instillation was the most common treatment (n = 56) but 27 HR-NMIBC did not receive specific treatment after TUR. Five and 10 years overall survival was 52% 42–63 and 41% 31–51, respectively. Five years net survival was 63% 47–75. Despite National cancer plans aiming to improve care giving and despite the severity of HR-NMIBC, guideline-recommended patterns of care were underused in this region. This may deserve attention to identify obstacles to guideline adoption to try to improve BC patient care and survival. 3
Saint et al. (Wed,) studied this question.